Want to cure your Hidradenitis Suppurativa in less than 2 months?

Antibiotica Bij Hidradenitis

Hidradenitis suppurativa (HS) is a painful, inflammatory, debilitating skin disease with a chronic intermittent course. The central pathogenetic event seems to be the occlusion of the hair follicle. HS has a 1-year prevalence of about 1%. It typically presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body: most commonly the axillae, inguinal, and anogenital regions. HS has a high negative impact on patients’ quality of life even in patients with only limited disease burden, and the diagnosis of HS is often made with a long diagnostic delay. In this practical short version we present diagnostic and therapeutic recommendations which are based on a systematic literature search as well as an informal expert consensus of Swiss dermatologists and dermatosurgeons.

© 2017 S. Karger AG, Basel

Description of the Disease and Epidemiology

Hidradenitis suppurativa (HS), also called “acne inversa” or “maladie de Verneuil,” is a painful, inflammatory, debilitating skin disease with a chronic intermittent course. It typically presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body: most commonly the axillae, inguinal and anogenital regions [1]. Population-based studies in European countries suggest a 1-year prevalence of HS of about 1% in the general population, with estimates ranging from 0.1 to 4% globally. HS commonly presents after puberty, with the average age of onset between 21 and 23 years of age, and is more common in women, with a female to male ratio between 2:1 and 5:1 [2,3]. Associations have also been reported with other inflammatory diseases, such as inflammatory bowel disease [4], pyoderma gangrenosum [5], and polycystic ovary syndrome [6].

The exact pathogenetic mechanism of HS remains unclear. Potential causes are related to genetic, environmental, endocrine, and microbiological factors. For example, HS can sometimes follow an autosomal dominant pattern of inheritance [7,8], and a total of 35-40% of patients report a family history of the disease. Several studies have pointed to higher than average smoking rates among HS patients (70-90%), and the severity and course of HS are correlated with body mass index. Due to its typical onset during puberty, an endocrine component has been suggested [9]. Finally, with regards to a possible microbial cause, a number of bacteria have been isolated from HS lesions. However, it is unclear whether bacteria are causal to disease pathogenesis or secondary, and hence infection is unlikely to be a primary causative factor [10]. Based on histopathological examination of HS biopsies, it is generally proposed that HS is initiated due to occlusion of the terminal hair follicle in response to hyperkeratinization, leading to nodule or cyst formation, and eventually a ruptured follicular epithelium, resulting in chronic inflammation with sinus and fistula formation and extensive dermal scarring [10,11,12,13,14].

Clinical Presentation and Diagnosis

HS is characterized by recurrent inflammation occurring more than 2-3 times in the last 6 months in the inverse regions of the body, presenting with nodules, sinus tracts and/or scarring [15]. The disease is most frequently localized in the axillary and inguinofemoral regions. The typical areas of involvement in males and females and their prevalence are listed in Table 1 [16,17]. In some cases atypical localizations on the ears, chest, and back are observed [18].

Table 1

Typical anatomical locations of lesions in hidradenitis suppurativa (HS) as described by Canoui-Poitrine et al. [17]


The diagnosis of HS is usually made by clinical examination, and in most cases skin biopsies are not required. However, they may be useful to rule out a differential diagnosis with a gram-positive bacterial cause (e.g., furuncle or carbuncle). The diagnostic criteria are summarized in Table 2 and rely on the 3 main features of HS as previously reported [19]:

Table 2

Diagnostic criteria for hidradenitis suppurativa (HS)


1. Typical anatomical location: axillae and inguinocrural regions – symmetrical lesions suggest systemic disease versus local infection.

2. Relapses and chronicity.

3. Typical lesions: deep-seated nodules (blind boils), comedones, and/or fibrosis.

While there is no consensus among the outcome measures used for HS, the most widely used disease activity scores are the Hurley staging and the Sartorius scoring system [20]. Hurley scoring is usually assigned to 3 stages:

Stage I: abscess formation, single or multiple, without sinus tracts and cicatrization.

Stage II: recurrent abscesses with tract formation and cicatrization, single or multiple, with widely separated lesions.

Stage III: diffuse or near-diffuse involvement, or multiple interconnected tracts and abscesses across the entire area.

Hurley stage I disease is most common (65% of cases), followed by stage II (31% of cases) and stage III (4% of cases) [20].

The Sartorius score is a dynamic scoring system created by Sartorius et al. [21,22] and later modified. Individual nodules and fistulas are counted, allowing a dynamic measurement of the clinical disease severity.

The diagnosis of HS is complicated due to the substantial variability in its course, making treatment challenging and resulting in a wide heterogeneity in response to treatment. It has been proposed that this might be due to undetected clinical subtypes of the disease. However, these subtypes have not yet been associated with distinct pathogenic mechanisms or differential responses to therapy [10]. Thus, future research will be required to untangle these differences in an effort to optimize treatment.

Course and Burden of Disease

HS is a chronic relapsing disease. If not treated adequately it may lead to serious complications such as bacterial infections, fistula formation, contractures and limb mobility limitations, squamous cell carcinoma, depression, anemia, malaise, and social impairment [23]. Indeed, it has been reported to prevent patients from working during disease flares [24], and the purulent discharge can produce an odor and stain clothing, resulting in social stigma [25]. Scarring can also cause considerable disability [20]. A recent study showed that the effect of HS on the Dermatology Life Quality Index (DLQI) was 5.77 ± 4.59 (mean ± SD) for patients with Hurley stage I disease, 13.1 ± 6.41 for patients with Hurley II, and 20.4 ± 6.67 for patients with Hurley III. This is very high compared to a wide spectrum of other dermatological diseases [26]. For example, moderate to severe psoriasis has a mean DLQI reported at 12-13 [27].

Among patient-reported signs and symptoms, pain was reported by 85% of individuals with HS to be the most bothersome, followed by swelling/inflammation (20%) and sensitivity/tenderness (10%) [28].

In addition to effects on quality of life, there is also a long diagnostic delay associated with HS. In one prospective survey study, the average patient delay in seeing a physician was 2.5 ± 5.0 years for individuals with HS compared to 1.0 ± 4.3 years for individuals with psoriasis. The diagnostic delay was 7.2 ± 8.7 years in HS versus 1.6 ± 4.8 years in psoriasis. Furthermore, individuals with HS typically see many more physicians than psoriasis patients prior to receiving their diagnosis [29].

Risk Factors and Comorbidities

Among all risk factors for HS studied to date, the strongest correlation among biological factors is obesity, while the strongest environmental association is with smoking. Revuz et al. [2] found an odds ratio (OR) of 4.42 for obesity (BMI >30) and 12.55 for smoking compared to healthy controls. Another study by Miller et al. [30] found an OR of 6.38 for obesity. In line with this, individuals with diabetes mellitus (OR = 5.74) and metabolic syndrome (OR = 3.89) also have a strong positive association with HS [30]. Individuals with HS also suffer from a significantly higher rate of cardiovascular risk factors compared to healthy controls [31].

With respect to disease progression, 5 risk factors were associated with an increased risk of progression from Hurley stage I to stage II or III in a retrospective study of 846 Dutch individuals with HS. These included male gender, disease duration, BMI, smoking pack-years, and lesion location (with axillary, inguinal, and mammary lesions having the highest OR) [32].

In addition, mechanical irritation and friction may also trigger HS [33,34], and the co-occurrence of HS with polycystic ovary syndrome, Crohn disease [35], and depression is statistically significant [36].

Treatment Options

Because smoking and obesity show the strongest correlation with disease severity [2], there is a general consensus that individuals with HS be advised and supported in the cessation of smoking and in reducing their body weight. Furthermore, loose-fitting clothing in order to avoid mechanical stress and friction is recommended. HS has a strongly negative impact on quality of life, including depression and problems with social integration. Although there are no studies proving efficacy on HS disease course, psychosocial support measures should be considered.

Clinical practice recommendations for medical treatment are summarized in Figure 1. To avoid bacterial superinfections and reduce inflammation, maceration and/or topical disinfectants (e.g., triclosan, ammonium bituminosulfonate) or topical antibiotics (e.g., clindamycin solution [37]) are suggested. Inflamed nodules may be injected with intralesional steroids. If topical agents are not sufficient, systemic antibiotics are typically given. Doxycycline (50-200 mg daily for 3-6 months) or rifampicin combined with clindamycin (each 300 mg twice daily [38]) for up to 3 months are suggested. Zinc gluconate (3 × 30 mg daily) may be added in combination. If antibiotics are not sufficient or no longer effective, the Swissmedic-approved dose of adalimumab should be considered (160 mg at week 1, 80 mg at week 2, and thereafter 40 mg weekly) [39]. Alternatively, a recent study showed improvements with systemic acitretin at a dosage of 0.2-0.5 mg/kg per day [40]. Many other agents may be used in patients with refractory disease; these include dapsone (50-150 mg daily), metformin, systemic steroids, or cyclosporine A.